Email ID
Password
Scrip   
Cephalon acquires Chinese rights to bendamustine
09 April 2009
Ian Haydock

Cephalon has acquired Chinese rights to the anticancer product bendamustine from SymBio Pharmaceuticals, a Japanese bioventure.

The sublicence will allow the US firm to exclusively develop and commercialise the alkylating agent in both mainland China and Hong Kong. Cephalon already markets...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36